Is Climb Bio, Inc. (CLYM) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.1% / 30% | 30.8% / 30% | 0.2% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 0.1% / 33% | 30.8% / 33% | 0.2% / 33% | N/A | ✓ HALAL |
| MSCI | 0.2% / 33% | 69.5% / 33% | 0.5% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.1% / 33% | 30.8% / 33% | 0.2% / 33% | N/A | ✓ HALAL |
| FTSE | 0.2% / 33% | 69.5% / 33% | 0.5% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -32.1% | |
| Return on Assets (ROA) | -22.0% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$54M |
| Free Cash Flow | -$55M |
| Total Debt | $541,000 |
| Debt-to-Equity | 0.3 |
| Current Ratio | 15.2 |
| Total Assets | $168M |
Price & Trading
| Last Close | $7.11 |
| 50-Day MA | $6.02 |
| 200-Day MA | $3.14 |
| Avg Volume | 665K |
| Beta | -0.2 |
|
52-Week Range
$1.05
| |
About Climb Bio, Inc. (CLYM)
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN) and other B-cell mediated diseases. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Climb Bio, Inc. (CLYM) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Climb Bio, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Climb Bio, Inc.'s debt ratio?
Climb Bio, Inc.'s debt ratio is 0.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.2%.
What are Climb Bio, Inc.'s key financial metrics?
Climb Bio, Inc. has a market capitalization of $479M. Return on equity stands at -32.1%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.